Stocks Health care ATRC
NASDAQ · Health careAtriCure, Inc. (ATRC)
AtriCure, Inc. brought in $589.8M of revenue over the twelve months to September 30, 2026, up 13.8% from a year earlier. Net income was $14.9M, a net margin of 2.5%. Operating cash flow minus capital spending left $48.3M of free cash flow in fiscal 2025. At September 30, 2026 it held $187M in cash against $61M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about AtriCure, Inc.
- Net worth
- AtriCure, Inc. has a market value (market cap) of $2.9B at the latest share price, and shareholders' equity of $533.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $534.5M (+14.9% year on year), with a net loss of $11.4M. Over the 12 months to September 30, 2026: revenue $589.8M, net income $14.9M.
- Cash flow
- In fiscal 2025 operations brought in $57.3M of cash; after $9.1M of capital spending, free cash flow was $48.3M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- AtriCure, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What AtriCure, Inc. does
AtriCure, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker ATRC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $534.5M | -$11.4M | -$0.24 | $48.3M |
| 2024 | $465.3M | -$44.7M | -$0.95 | $745K |
| 2023 | $399.2M | -$30.4M | -$0.66 | -$7.5M |
| 2022 | $330.4M | -$46.5M | -$1.02 | -$39M |
| 2021 | $274.3M | $50.2M | $1.09 | -$23.5M |
| 2020 | $206.5M | -$48.2M | -$1.14 | -$25.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ATRC ranks in Health care
Latest SEC filings
What AtriCure, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 15% to $154.5M versus the same quarter last year; diluted EPS $0.08 versus -$0.01.
- November 3, 2026
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 5, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 27, 2026
- July 27, 2026
- July 27, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 13% to $153.6M versus the same quarter last year; diluted EPS $0.18 versus -$0.13.
- July 23, 2026
- May 27, 2026
What is ATRC worth? A DCF from its reported cash flow
Insider trades
What the people running AtriCure, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.2M worth of shares in the last 90 days and bought none on the open market. Most of the selling (66%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Privitera SalvatoreChief Technical Officer | Soldpre-planned (10b5-1) | 8,404 | $546.3K |
| September 23, 2026 | Privitera SalvatoreChief Technical Officer | Soldpre-planned (10b5-1) | 4,519 | $271.1K |
| September 11, 2026 | Groves Regina EDirector | Sold | 5,313 | $288.1K |
| September 8, 2026 | Privitera SalvatoreChief Technical Officer | Soldpre-planned (10b5-1) | 3,657 | $201.1K |
| September 2, 2026 | Privitera SalvatoreChief Technical Officer | Soldpre-planned (10b5-1) | 7,763 | $407.6K |
| August 24, 2026 | Dahlquist Karl S.Chief Legal Officer | Sold | 9,370 | $458.1K |
| August 5, 2026 | Prange KarenDirector | Sold | 3,564 | $138.3K |
| August 5, 2026 | Yuen MaggieDirector | Sold | 3,500 | $134.5K |
Who owns ATRC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Wellington Management Group LLP13G, passive with 3 related filers | 6.8% | May 15, 2026 |
| Hood River Capital Management LLC13G, passive | 6.23% | February 17, 2026 |
| Vanguard Portfolio Management13G, passive | 5.51% | April 28, 2026 |
| AllianceBernstein L.P.13G, passive | 5.5% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.08% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 252 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 4,474,548 | +431,867 |
| Wellington Management Group Llp | 3,495,603 | +113,048 |
| Vanguard Portfolio Management LLC | 3,127,195 | +424,563 |
| Hood River Capital Management LLC | 2,905,299 | -212,246 |
| Alliancebernstein L.P. | 2,768,365 | -490,507 |
| Vanguard Capital Management LLC | 2,190,413 | +34,649 |
| Nomura Asset Management International Inc. | 1,734,279 | -70,648 |
| Goldman Sachs Group Inc | 1,597,988 | -69,178 |
| State Street Corp | 1,389,989 | +87,827 |
| Marshall Wace, Llp | 1,333,904 | -133,620 |
| Geode Capital Management, LLC | 1,319,687 | +93,571 |
| Arrowstreet Capital, Limited Partnership | 1,296,209 | +1,018,527 |
| Dimensional Fund Advisors LP | 1,044,034 | +46,275 |
| Neuberger Berman Group LLC | 947,982 | -102,300 |
| Champlain Investment Partners, LLC | 938,567 | -32,544 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 897,419 | -163,387 |
| Bank of America Corp | 874,370 | +105,809 |
| Kennedy Capital Management LLC | 857,787 | +23,632 |
| Divisadero Street Capital Management, LP | 800,931 | -359,024 |
| Point72 Asset Management, L.P. | 604,380 | new |
Insiders
15 insiders reported holding 1,966,727 shares in total, about $110.6M at the last price.
| Holder | Shares |
|---|---|
| Carrel Michael HPresident, CEO, & Director, Director | 774,434 |
| Seith Douglas JChief Operating Officer | 229,867 |
| Wirick Angela LChief Financial Officer | 204,893 |
| Privitera SalvatoreChief Technical Officer | 134,341 |
| White Robert S.Director | 128,318 |
| Noznesky Justin JChief Mktg & Strategy Officer | 100,219 |
| Dahlquist Karl S.Chief Legal Officer | 87,319 |
| Doraiswamy VinayakChief Scientific Officer | 86,511 |
| Johnson B KristineDirector | 55,954 |
| Wehrwein SvenDirector | 40,518 |
Questions about ATRC
What does AtriCure, Inc. do?
AtriCure, Inc. is a company in the Health care sector, listed on NASDAQ as ATRC. Its shares trade on NASDAQ under the ticker ATRC.
What is AtriCure, Inc.'s net worth?
AtriCure, Inc. has a market value (market cap) of $2.9B at the latest share price, and shareholders' equity of $533.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is AtriCure, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $14.9M on revenue of $589.8M, a net margin of 2.5%.
How much revenue does AtriCure, Inc. make?
Over the twelve months to September 30, 2026 AtriCure, Inc. reported revenue of $589.8M. That is 13.8% more than a year earlier.
When did AtriCure, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 6, 2026.
When is AtriCure, Inc.'s next earnings report?
AtriCure, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ATRC with
Follow ATRC
Get an email when AtriCure, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values AtriCure, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.